Eye complications of cetuximab therapy
Language English Country Great Britain, England Media print
Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't
PubMed
17760931
DOI
10.1111/j.1365-2354.2006.00763.x
PII: ECC763
Knihovny.cz E-resources
- MeSH
- Cetuximab MeSH
- Adult MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Colorectal Neoplasms drug therapy MeSH
- Drug Eruptions etiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Antibodies, Monoclonal administration & dosage adverse effects MeSH
- Eye Diseases chemically induced MeSH
- Antineoplastic Agents administration & dosage adverse effects MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Cetuximab MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Antibodies, Monoclonal MeSH
- Antineoplastic Agents MeSH
Skin toxicity is the most important side effect of cetuximab administration, but little is known about the eye toxicity, including periorbital skin. We present here four cases of patients with metastatic colorectal carcinoma treated with the combination of cetuximab, irinotecan, 5-fluorouracil and leucovorin who had manifestation of complications in the eye or periorbital skin. These manifestations consisted of erythematous eruptions in the periorbital skin with blepharitis and conjunctivitis in three patients and trichomegaly in one patient. The symptoms were controlled with local therapy including corticosteroids and antibiotics. The skin toxicity in the periorbital region is more important than in other skin areas because of the impact on the social activity of the patient and the vision. The manifestations of eye toxicity of cetuximab may be controlled by local therapy, and the management of these patients requires the collaboration of medical oncologist and ophthalmologist.
References provided by Crossref.org
Neopterin as a biomarker of immune response in cancer patients
Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy